Research Report on Medical Appliances & Equipment Equities -- Abbott Laboratories, Boston Scientific, Medtronic, and Hologic

30 Aug, 2016, 07:35 ET from Chelmsford Park SA

NEW YORK, August 30, 2016 /PRNewswire/ --

The Medical Appliances and Equipment industry includes companies that manufacture medical instruments such as dental and surgical appliances. Stocks in this space tend to offer below-average dividend yields when compared to the wider market. Stock-Callers.com now reviews the recent performances of the following equities: Abbott Laboratories (NYSE: ABT), Boston Scientific Corp. (NYSE: BSX), Medtronic PLC (NYSE: MDT), and Hologic Inc. (NASDAQ: HOLX). Learn more about these stocks by accessing their free research reports at:

http://stock-callers.com/registration

Abbott Laboratories  

Abbott Park, Illinois headquartered Abbott Laboratories' shares gained 0.63%, closing Monday's trading session at $43.25. The stock recorded a trading volume of 9.19 million shares. Shares of the Company have advanced 9.81% in the previous three months. The stock is trading 2.25% above its 50-day moving average and 5.49% above its 200-day moving average. Additionally, shares of Abbott Laboratories, which manufactures and sells health care products worldwide, have a Relative Strength Index (RSI) of 46.62.

On August 26th, 2016, Bloomberg reported that Alere Inc. sued Abbott Laboratories to compel the completion of their pending $5.8 billion takeover deal, claiming the medical-device maker failed to get U.S. antitrust clearance in an effort to scuttle the contentious transaction. Abbott "has breached the merger agreement between the parties by failing to promptly secure antitrust approvals and other regulatory requirements," Alere said in a filing in Delaware Chancery Court, as per the article. Free research report on ABT is available at:

http://stock-callers.com/registration/?symbol=ABT

Boston Scientific  

On Monday, shares in Marlborough, Massachusetts headquartered Boston Scientific Corp. recorded a trading volume of 6.90 million shares. The stock rose 1.38%, ending the day at $24.30. The Company's shares have advanced 0.08% in the last month, 7.00% in the previous three months, and 31.78% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.76% and 19.94%, respectively. Furthermore, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have an RSI of 58.20.

On August 9th, 2016, Boston Scientific announced that it has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance conditional labeling for all previously implanted EMBLEM S-ICD Systems. The EMBLEM S-ICD System is a proven treatment option for patients at risk of sudden cardiac arrest, that leaves the heart and vasculature untouched, thus reducing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillator leads. The complimentary research report on BSX can be downloaded at:

http://stock-callers.com/registration/?symbol=BSX

Medtronic  

Dublin, Ireland headquartered Medtronic PLC's stock finished the day 0.99% higher at $87.46 with a total trading volume of 3.71 million shares. The Company's shares have gained 9.21% in the previous three months and 14.85% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 0.70% and 10.26%, respectively. Additionally, shares of Medtronic, which manufactures and sells device-based medical therapies worldwide, have an RSI of 52.86.

On August 26th, 2016, Medtronic announced that, in connection with the completion of the acquisition of HeartWare by Medtronic, HeartWare has commenced an offer to repurchase, at the option of each holder, any and all of its outstanding 3.50% Convertible Senior Notes due 2017 and 1.75% Convertible Senior Notes due 2021.

On August 26th, 2016, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $93 a share to $95 a share. Visit us today and access our complete research report on MDT at:

http://stock-callers.com/registration/?symbol=MDT

Hologic  

Shares in Marlborough, Massachusetts headquartered Hologic Inc. ended yesterday's session 0.18% lower at $38.73. The stock recorded a trading volume of 1.88 million shares. The Company's shares have advanced 0.62% in the last one month, 12.55% over the previous three months, and 0.10% on an YTD basis. The stock is trading 5.30% and 7.31% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, the Asia-Pacific, and internationally, have an RSI of 60.30.

On August 27th, 2016, Reuters reported that the FDA recommended that all blood donated in the US and its territories be tested for Zika virus. In states and territories with local, mosquito-borne transmission, the recommendations will go into effect immediately. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said that Hologic and Roche Molecular Systems had been granted special approval for their tests to be used to screen the blood supply.

On August 01st, 2016, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with an increase of the target price from $37 a share to $39 a share. Get free access to your research report on HOLX at:

http://stock-callers.com/registration/?symbol=HOLX

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA